Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide. 2003

Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
Division of Molecular Analysis of Human Disorders, Department of Bio-signal Analysis, Yamaguchi University Graduate School of Medicine, Ube.

A 21-year-old woman with Cushing's syndrome presented with a mediastinal tumor. Ectopic ACTH syndrome was diagnosed and the tumor was resected. The histopathological diagnosis was thymic atypical carcinoid. Despite all tumor lesions having been resected, the tumor relapsed and multiple metastatic lesions grew aggressively. Combination chemotherapy with cisplatin and etoposide (VP16) was administered to control tumor progression, and achieved marked therapeutic effects. Maintenance chemotherapy with carboplatin and VP16 achieved long-term tumor control. This case indicates that some patients with atypical carcinoid tumor are good responders to chemotherapy with platinum agents and VP16.

UI MeSH Term Description Entries
D002276 Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182) Argentaffinoma,Carcinoid,Carcinoid, Goblet Cell,Argentaffinomas,Carcinoid Tumors,Carcinoids,Carcinoids, Goblet Cell,Goblet Cell Carcinoid,Goblet Cell Carcinoids,Tumor, Carcinoid,Tumors, Carcinoid
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000182 ACTH Syndrome, Ectopic Symptom complex due to ACTH production by non-pituitary neoplasms. Ectopic ACTH Syndrome,ACTH Syndromes, Ectopic,Ectopic ACTH Syndromes,Syndrome, Ectopic ACTH,Syndromes, Ectopic ACTH
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D013953 Thymus Neoplasms Tumors or cancer of the THYMUS GLAND. Cancer of Thymus,Thymus Cancer,Thymus Tumors,Cancer of the Thymus,Neoplasms, Thymic,Neoplasms, Thymus,Thymic Cancer,Thymic Neoplasms,Thymic Tumors,Cancer, Thymic,Cancer, Thymus,Cancers, Thymic,Cancers, Thymus,Neoplasm, Thymic,Neoplasm, Thymus,Thymic Cancers,Thymic Neoplasm,Thymic Tumor,Thymus Cancers,Thymus Neoplasm,Thymus Tumor,Tumor, Thymic,Tumor, Thymus,Tumors, Thymic,Tumors, Thymus

Related Publications

Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
January 2002, Acta clinica Belgica,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
April 1996, Nihon Kyobu Shikkan Gakkai zasshi,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
January 1999, Journal of pediatric endocrinology & metabolism : JPEM,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
January 2019, Northern clinics of Istanbul,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
July 2009, Clinical nuclear medicine,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
April 2006, Journal of endocrinological investigation,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
January 2006, The Netherlands journal of medicine,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
August 2000, The Israel Medical Association journal : IMAJ,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
January 1981, Acta clinica Belgica,
Toru Takahashi, and Katsuhiro Hatao, and Yoshimi Yamashita, and Yukio Tanizawa
June 1998, Indian journal of cancer,
Copied contents to your clipboard!